See the DrugPatentWatch profile for keytruda

Keytruda, also known as pembrolizumab, is an immunotherapy drug used to treat various types of cancer. It works by blocking a protein called PD-1, which allows the immune system to identify and destroy cancer cells. However, immunocompromised individuals may be at risk with Keytruda infusions due to the drug's potential to impact the immune system's ability to fight off infections [1].

Immunocompromised individuals have weakened immune systems, making them more susceptible to infections and complications. Keytruda can further weaken the immune system by affecting the body's T-cells, which are crucial for fighting off infections. As a result, immunocompromised patients may be at a higher risk of developing severe infections and experiencing adverse reactions to the drug [1].

Additionally, Keytruda can cause immune-related adverse effects, such as inflammation of the lungs, colon, and other organs. These adverse effects can be more severe in immunocompromised individuals, as their weakened immune systems may not be able to effectively combat the inflammation [1].

It is important for healthcare providers to closely monitor immunocompromised patients receiving Keytruda infusions and to take appropriate measures to reduce the risk of infections and adverse reactions. This may include administering prophylactic antibiotics, monitoring white blood cell counts, and closely monitoring patients for signs of infection or immune-related adverse effects [1].

In conclusion, immunocompromised individuals may be at risk with Keytruda infusions due to the drug's potential to impact the immune system's ability to fight off infections. Healthcare providers should closely monitor these patients and take appropriate measures to reduce the risk of adverse reactions.

Sources:

1. DrugPatentWatch.com. (2022). Keytruda (Pembrolizumab) - DrugPatentWatch. Retrieved from <https://www.drugpatentwatch.com/drugs/keytruda>